Xencor, Inc.
Clinical trials sponsored by Xencor, Inc., explained in plain language.
-
New drug trial offers hope for ulcerative colitis sufferers
Disease control Recruiting nowThis study tests a new drug called XmAb942 for people with moderate-to-severe ulcerative colitis, a condition that causes inflammation in the colon. First, healthy volunteers will help check the drug's safety. Then, about 270 people with ulcerative colitis will receive the drug o…
Phase: PHASE1, PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated May 26, 2026 02:22 UTC
-
New injection aims to tame autoimmune attacks
Disease control Recruiting nowThis early-stage study tests a new drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma or Sjögren's. The main goal is to check if the drug is safe and tolerable when given as an injection under the skin. Researchers w…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated May 26, 2026 02:21 UTC
-
New hope for kidney cancer: experimental drug XmAb819 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called XmAb819 in people with advanced clear cell kidney cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug intrav…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated May 26, 2026 02:20 UTC
-
New drug XmAb541 enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to prior treatments. The main goals are to check if the drug is safe and to find the best dose. About 282 participants will take part i…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New injection for arthritis pain enters early human testing
Symptom relief Recruiting nowThis early-stage study tests a new drug called plamotamab in 68 adults with moderate to severe rheumatoid arthritis who have not responded well to other treatments. The main goal is to check the drug's safety and side effects when given as an injection under the skin. Researchers…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Symptom relief
Last updated May 18, 2026 12:09 UTC